Summary
ADMS Chart
Time Sensitive - Reminder from Levi & Korsinsky, LLP to File Claim for Share of Adamas Pharmaceuticals, Inc. (ADMS) Settlement Fund Before Deadline
NEW YORK, NY / ACCESSWIRE / June 27, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). The settlement provides for a fund of $4,650,000 to benefit class members.
$4,650,000 Recovery from Adamas Pharmaceuticals, Inc. (ADMS). L&K, LLP Reminds Shareholders to File a Claim Before Deadline
NEW YORK, NY / ACCESSWIRE / June 25, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). The settlement provides for a fund of $4,650,000 to benefit class members.
Deadline Approaching for Receiving Share of Adamas Pharmaceuticals, Inc. (ADMS) Recovery - Contact Levi & Korsinsky, LLP for Further Details
NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The settlement provides for a fund of $4,650,000 to benefit class members.
Adamas Pharmaceuticals Inc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Jeffrey Gundlach DoubleLine Capital LP | 100,000 | $412,000 | $412,000 | - | - |
